Navigation Links
DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
Date:1/8/2008

Patent Protects Very Low Dose Glucagon ahead of Phase 2 Clinical Trials in

2008

SAN FRANCISCO, Jan. 8 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced today that it has secured a critical patent from the U.S. Patent and Trademark Office for the use of very low dose glucagon, or DIO-901, in the prevention of insulin-induced hypoglycemia in diabetes patients. The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon.

"This patent protection strengthens our commitment to delivering the first product to the market for the prevention of insulin-induced hypoglycemia in diabetes," CEO David Cory said. "DIO-901 is the only therapeutic in development to prevent insulin-induced hypoglycemia, which is known to limit optimal glycemic control and cause recurring medical complications in most people with type 1 diabetes, in many with type 2 diabetes, and is sometimes fatal."

Insulin-induced hypoglycemia is the limiting factor in the glycemic management of diabetes. Were it not for the barrier of hypoglycemia, people with diabetes might achieve normal HbA1c levels over a lifetime of diabetes. Reduction of mean glycemia over time prevents or delays microvascular complications -- retinopathy, nephropathy, and neuropathy -- in both type 1 and type 2 diabetes. DIO-901 is expected to begin Phase 2 clinical testing later this year and has received Fast Track status from the Food and Drug Administration, underscoring the great unmet medical need in the prevention of insulin-induced hypoglycemia.

DiObex's latest patent, U.S. Patent No. 7,314,859, builds on a growing patent portfolio protecting its product candidates for metabolic diseases. In addition to the recently issued U.S. patent, DiObex owns seven U.S. patent applications and 30 corresponding foreign patent applications relating to DIO-901. DiObex also owns or has exclusively licensed seven U.S. patents, five U.S. patent applications, and more than 100 issued foreign patents and pending foreign and international patent applications relating to DIO-902.

About DiObex

DiObex, Inc. is a privately held San Francisco-based biotechnology company developing novel products for diabetes and metabolic diseases. DiObex has two product candidates in four mid-stage clinical development programs. DIO-901 (very low dose glucagon) is in development for the prevention of insulin-induced hypoglycemia in type 1 diabetes mellitus in an extended release subcutaneous formulation and as a convenient continuous subcutaneous infusion. DIO-901 has received Fast Track status from the FDA. DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole that is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit http://www.diobex.com.


'/>"/>
SOURCE DiObex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
2. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
3. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
6. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
7. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
8. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
9. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
10. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
11. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president of ... In his new role, Marziani will lead the company,s business development and sales team, ... outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... de COMBO ™ , la ... présentent des cathéters destinés à l,intervention portant ... artério-veineuse (FAV)   OrbusNeich, entreprise ... vasculaires permettant de changer la vie, a ...
(Date:5/24/2016)... Een app die artsen over ... patiënten kunnen behandelen, hun kennis kunnen delen en van ... nieuwe en revolutionaire MDLinking App, ontwikkeld door een internationale ... Hans Flu en oncologisch chirurg dr. Gijs van ... wordt op dinsdag 24 mei officieel gepresenteerd op het ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... DKT International, one of the ... is pleased to release their 2015 global impact data. In 2015, DKT served ... maternal deaths and 3.8 million unsafe abortions across 21 countries worldwide. , ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad Siegel Actuaries, delivering comprehensive ... Prescription Drug survey , an employee benefits survey measuring how Central ... December 2015, indicates that employers are turning to consumer directed health care and ...
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows users to ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... add stylish color grades to their footage. A LUT is a Lookup Table that ...
(Date:5/25/2016)... Atlanta GA (PRWEB) , ... May 25, 2016 ... ... workplace solutions builder, has announced that it will join America's leading engineers at ... will be held at the Georgia World Congress Center. , Engineers, speakers ...
(Date:5/24/2016)... ... May 24, 2016 , ... BTC Media, ... blockchain event, Distributed: Health, to be held in Nashville, Tennessee on September 7, ... A 24-hour Hackathon preceding the event will host teams from around the world, ...
Breaking Medicine News(10 mins):